Gustav Christensen

Gustav Christensen is an experienced executive in the biotechnology and pharmaceutical industries, currently serving as Chairman of the Board at Morphic Therapeutic since March 2016 and as Director at Generation Bio since August 2017. Previously, Gustav held the position of President and Chief Executive Officer at Dyax from April 2007 to February 2016. Additional roles include Managing Director at Apeiron Partners, Director at Alantos Pharmaceuticals (which was acquired by Amgen), Director at Cohesive Technologies (acquired by Thermo Fisher Scientific), and President and CEO at Phylos (acquired by Compound Therapeutics). Gustav also served as Chairman at Primedica (acquired by Charles River Labs) and Director at Phytera, Inc. and has held the position of Chairman at Alpha Beta Technology. Academic qualifications include a Master of Business Administration from Harvard Business School and a cand. oecon in Economics from Aarhus University.